Synapse - Paul Hamlin

Results (293)

Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma

Journal Article

Kumar, A.; Casulo, C.; Yahalom, J.; Schöder, H.; Barr, P. M.; Caron, P.; Chiu, A.; Constine, L. S.; Drullinsky, P.; Friedberg, J. W.; more...
Blood (2016)

Fulltext@MSK | Save

Phase 1 final results and phase 2a dose selection for cerdulatinib (Prt062070) a dual SYK/JAK inhibitor in patients with relapsed/refractory B cell malignancies

Meeting Abstract

Hamlin, P.; Flinn, I.; Wagner-Johnston, N.; Burger, J.; Michelson, G.; Pandey, A.; Birrell, M.; Coffey, G.; Leeds, J.; Sabalvaro-Torres, A.; more...
Haematologica (2016)

Fulltext@MSK | Save

Central nervous system involvement in T-cell lymphoma: A single center experience

Journal Article

Gurion, R.; Mehta, N.; Migliacci, J. C.; Zelenetz, A.; Moskowitz, A.; Lunning, M.; Moskowitz, C.; Hamlin, P.; Horwitz, S.
Acta Oncologica (2016)

Fulltext@MSK | Save

Prospective study of 3′-deoxy-3′-(18)F-fluorothymidine PET for early interim response assessment in advanced-stage B-cell lymphoma

Journal Article

Schoder, H.; Zelenetz, A. D.; Hamlin, P.; Gavane, S.; Horwitz, S.; Matasar, M.; Moskowitz, A.; Noy, A.; Palomba, L.; Portlock, C.; more...
Journal of Nuclear Medicine (2016)

Fulltext@MSK | Save

Central nervous system involvement in T-cell lymphoma: A single center experience

Meeting Abstract

Mehta, N.; Gurion, R.; Maragulia, J.; Zelenetz, A.; Moskowitz, A.; Moskowitz, C.; Hamlin, P.; Horwitz, S.
Clinical Lymphoma, Myeloma and Leukemia (2015)

Fulltext@MSK | Save

Veliparib (ABT-888), bendamustine, and rituximab (VBR) is well tolerated and efficacious in patients with lymphoma: Final analysis of a phase 1b clinical trial of VB and a cohort expansion of VBR in patients with B-cell lymphoma

Meeting Abstract

Soumerai, J. D.; Zelenetz, A. D.; Moskowitz, C. H.; Younes, A.; Palomba, M. L.; Hamlin, P. A. Jr; Noy, A.; Horwitz, S. M.; Matasar, M. J.; Moskowitz, A. J.; more...
Blood (2015)

Fulltext@MSK | Save

Phase 1/1b study of the novel immunotoxin MT-3724 in relapsed/refractory non-Hodgkin's B-cell lymphoma (NHL)

Meeting Abstract

Hamlin, P. A.; Diefenbach, C. S.; Valacer, D. J.; Higgins, J.; Fanale, M. A.
Blood (2015)

Fulltext@MSK | Save

Clinical and correlative results of a phase 1 study of cerdulatinib (PRT062070) a dual SYK/JAK inhibitor in patients with relapsed/refractory B cell malignancies

Meeting Abstract

Hamlin, P. A.; Flinn, I.; Wagner-Johnston, N.; Burger, J. A.; Michelson, G.; Pandey, A.; Birrell, M.; Coffey, G. P.; Leeds, J. M.; Curnutte, J. T.; more...
Blood (2015)

Fulltext@MSK | Save

Defining the incidence and clinical impact of genomic alterations across different histologic types of lymphoma using a clinically validated comprehensive targeted sequencing assay

Meeting Abstract

Batlevi, C.; Rapaport, F.; Intlekofer, A. M.; Reiner, A.; Moskowitz, C. H.; Horwitz, S. M.; Zelenetz, A. D.; Palomba, L.; Moskowitz, A. J.; Gerecitano, J. F.; more...
Blood (2015)

Fulltext@MSK | Save

A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma

Journal Article

Wagner-Johnston, N. D.; Goy, A.; Rodriguez, M. A.; Ehmann, W. C.; Hamlin, P. A.; Radford, J.; Thieblemont, C.; Suh, C.; Sweetenham, J.; Huang, Y. F.; more...
Leukemia and Lymphoma (2015)

Fulltext@MSK | Save